stockrow
Sunday 8 November 2026
Export OGN’s income statement to Excel — free account
Organon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
13.87
0.08
+0.58%
Follow OGN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 5 | 5 |
+8 more TTM periods Free account |
| 20.30% | 24.04% | 34.05% | 30.56% | ||
| 1.58% | 1.57% | 1.88% | 1.44% | ||
ROIC |
6.26% | 6.11% | 6.18% | 5.84% | |
Return on Tangible Assets |
5.32% | 5.53% | 6.63% | 5.73% | |
Average Days of Receivables |
88.57 | 88.88 | 81.97 | 78.16 | |
Free Cash Flow per Share |
2.18 | 1.77 | 2.63 | 1.60 | |
Free Cash Flow |
572.00 | 464.00 | 684.00 | 415.00 | |
Capital Expenditures |
(271.00) | (273.00) | (166.00) | (285.00) | |
| Other line items | |||||
Cash ROIC |
5.11% | 4.34% | 6.46% | 4.16% | |
Accounts Receivable Turnover |
4.12 | 4.12 | 4.34 | 4.62 | |
Accounts Payable Turnover |
2.78 | 2.74 | 2.92 | 2.76 | |
Inventory Turnover |
2.01 | 2.07 | 2.13 | 2.13 | |
Average Days of Payables |
125.37 | 132.33 | 123.38 | 119.70 | |
Days of Inventory on Hand |
172.99 | 170.10 | 172.33 | 176.78 | |
Tax Rate |
(0.58) | (0.57) | (0.54) | (0.56) | |
Research and Development Expense of Revenue |
5.85% | 5.84% | 5.89% | 5.89% | |
Selling, General and Administrative Expense of Revenue |
28.07% | 27.84% | 27.99% | 27.69% | |
Share Based Compensation of Revenue |
1.18% | 1.22% | 1.17% | 1.24% | |
Interest Coverage |
1.86 | 1.76 | 1.68 | 1.63 | |
Operating CF/Net income |
3.96 | 3.53 | 3.46 | 3.74 | |
Depreciation/Fixed assets |
0.47 | 0.46 | 0.47 | 0.47 | |
Capex/Depreciation |
(0.45) | (0.47) | (0.28) | (0.47) | |
Revenue per Share |
23.22 | 23.33 | 23.67 | 23.95 | |
Operating CF per Share |
3.21 | 2.81 | 3.26 | 2.70 | |
Capex per Share |
(1.03) | (1.04) | (0.64) | (1.10) | |
Capex to Sales |
0.04 | 0.04 | 0.03 | 0.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026